FDA approves new Invokana indication
Janssen Pharmaceutical's Invokana (canagliflozin) has a new approved indication. The Food and Drug Administration has approved the product to reduce the risk of major adverse cardiovascular events, including heart attack, stroke or death due to a cardiovascular cause in adults with Type 2 diabetes who have established cardiovascular disease, the company recently announced.
Invokana is the first and only oral diabetes treatment approved with this indication, the company said.
“This FDA approval makes Invokana the only oral Type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or [cardiovascular] death. It is an important step forward for patients and the physicians who treat them,” said James List, Janssen research and development global therapeutic area head, cardiovascular and metabolism. “Not only does Invokana enable patients to control their diabetes symptoms by lowering their A1C levels, but it now also helps protect them from potentially devastating cardiovascular events.”
Invokana is the first and only oral diabetes treatment approved with this indication, the company said.
“This FDA approval makes Invokana the only oral Type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or [cardiovascular] death. It is an important step forward for patients and the physicians who treat them,” said James List, Janssen research and development global therapeutic area head, cardiovascular and metabolism. “Not only does Invokana enable patients to control their diabetes symptoms by lowering their A1C levels, but it now also helps protect them from potentially devastating cardiovascular events.”